Fracture Risk Up With Insulin Compared With Metformin in T2DM
Risk for major osteoporotic fractures up for insulin versus metformin for those with HbA1c <7 percent, BMI <25 kg/m2
Risk for major osteoporotic fractures up for insulin versus metformin for those with HbA1c <7 percent, BMI <25 kg/m2
Bioavailability is equivalent for levothyroxine oral solution administered five minutes prior to coffee or under fasting conditions
Guidelines address glycemic management in noncritically ill hospitalized adults with diabetes or newly recognized hyperglycemia
No evidence of increase seen for short- to medium-term cardiovascular risk, but data lacking regarding long-term safety
Mean glycated hemoglobin level at 26 weeks increased with placebo, decreased with dulaglutide among youth with BMI >85th percentile
Incidence rate of invasive disease-free survival events and incidence rates for death did not differ with addition of metformin, placebo
Fewer renal complications seen with tirzepatide versus insulin glargine in adults with T2D and increased cardiovascular risk
Updates include effects in T2D patients of finerenone on CV outcomes in those with CKD; of SGLT2 inhibitors on heart failure, renal outcomes
Moderate consumption of unsweetened coffee and sugar-sweetened coffee linked to reduced risk for all-cause mortality